News Feed

Researchers have identified a potential new treatment target in aggressive small cell cancers that have long resisted effective therapies. The study found that tumors missing the RB gene become highly dependent on a protein called E2F3 to survive. When researchers blocked E2F3 in laboratory models, tumor growth stopped, revealing a critical weakness that cancer cells rely on. Encouragingly, some existing FDA-approved drugs may already be able to target this pathway, potentially speeding up the development of new treatments. While more research and clinical trials are needed, this discovery offers fresh hope for improving outcomes in patients with these difficult-to-treat cancers.

A new study suggests that measuring apolipoprotein B (apoB) may be a better way to identify people at high risk of heart disease than relying on standard LDL ("bad") cholesterol alone. ApoB measures the number of harmful cholesterol-carrying particles in the blood, providing a more accurate picture of cardiovascular risk. Researchers found that using apoB to guide treatment decisions could prevent more heart attacks and strokes while remaining cost-effective for the healthcare system. Although current guidelines still primarily use LDL cholesterol, these findings support a growing role for apoB testing in helping doctors personalize treatment and improve heart disease prevention.

Scientists have uncovered the 3D structures of two unusual molecules found in rye pollen, solving a scientific mystery that has remained unanswered for nearly three decades. These natural compounds previously showed the ability to stimulate anti-tumor responses in animal studies, but their exact structures were unknown, limiting further research. With this breakthrough, researchers can now investigate how the molecules interact with the immune system and identify the features responsible for their potential cancer-fighting effects. Although the discovery is still at an early research stage and not a treatment, it provides an important foundation for developing future cancer immunotherapies inspired by natural plant compounds.

A large study involving more than 21,000 people with glaucoma suggests that genetic information could help identify those at high risk long before symptoms appear. Researchers used a polygenic risk score, which combines the effects of many genetic variants, to estimate each person's lifetime risk. Nearly half of those in the highest-risk group developed glaucoma, compared with fewer than 3% in the lowest-risk group. People with higher genetic risk also tended to develop more severe disease requiring additional medications, laser therapy, or surgery. While further research is needed, these findings could pave the way for personalized screening and earlier treatment to help prevent irreversible vision loss.

A large study using data from the UK Biobank suggests that higher blood glucose levels may accelerate brain aging. Researchers combined MRI brain scans, blood metabolomics, genetics, and artificial intelligence to identify factors linked to an "older-looking" brain. Among nine significant blood metabolites, glucose showed the strongest association with accelerated brain aging. Higher glucose levels were also linked to an increased risk of dementia, Alzheimer's disease, Parkinson's disease, stroke, depression, and poorer cognitive performance. While the findings do not prove cause and effect in humans, they highlight blood sugar control as a potentially modifiable factor that could help protect brain health and reduce the risk of age-related neurological disorders.

Researchers have developed an innovative biodegradable scaffold that restored normal skull growth in mouse models of craniosynostosis, a birth defect in which skull bones fuse too early. Unlike current surgeries that often lead to re-fusion, the new "bone-suture-bone" scaffold recreates the natural stem cell environment needed for healthy skull development. In the study, the implant prevented abnormal bone fusion, maintained skeletal stem cells, and significantly improved craniofacial growth. Although the research is still in animals, the findings offer hope for regenerative therapies that could treat the root cause of craniosynostosis and potentially improve outcomes for children with this condition.

A large review of 28 studies suggests that people with allergic diseases may have a slightly higher overall risk of developing cancer, though the increase is small. Researchers found the strongest association in people with asthma, while hay fever and atopic dermatitis showed no significant link. The relationship also varied by region and cancer type, with some cancers showing increased risk and others showing the opposite trend. Importantly, the findings do not prove that allergies cause cancer. Experts say more research is needed to understand the biological connection and identify which groups, if any, may face a meaningful increase in risk.

A new study has identified a previously overlooked mechanism that may explain how brain cells die in Alzheimer’s disease and frontotemporal dementia. Researchers believe this newly discovered pathway plays a major role in the progressive loss of neurons that drives memory decline and cognitive impairment. The discovery opens the door to developing treatments that target this cell-death process before irreversible damage occurs. Instead of only addressing symptoms, future therapies could potentially slow disease progression by protecting vulnerable brain cells. While more research and clinical testing are needed, these findings offer fresh hope for more effective treatments against devastating neurodegenerative diseases.

Researchers have uncovered how mutations in the ATRX gene help aggressive gliomas grow by reshaping the way DNA is folded and organized inside cancer cells. This altered DNA structure switches on genes that promote tumor growth, spread, and survival. In laboratory and animal studies, blocking one of these pathways - particularly the HOXA gene family—slowed tumor growth, triggered cancer cell death, and improved survival. The findings suggest that targeting the downstream effects of ATRX mutations, rather than the mutation itself, could offer a more precise treatment strategy. Although further clinical studies are needed, this discovery opens new possibilities for personalized therapies against hard-to-treat brain cancers.

A new study suggests that forcing treatment-resistant breast cancer cells to die through a process called necroptosis could do more than eliminate tumor cells - it may also boost the body's immune response. Using patient-derived 3D mini-tumors (organoids), researchers found that necroptosis caused cancer cells to release danger signals that activated immune pathways, including those involving natural killer (NK) cells, which help destroy tumors. Unlike apoptosis, a "silent" form of cell death, necroptosis alerts the immune system, potentially strengthening anti-cancer defenses. These findings highlight a promising strategy for future cancer therapies while showcasing organoids as powerful models for studying disease and testing new treatments.